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Type I interferons (IFNs) were originally identiﬁed as antiviral effector molecules that exert
pleiotropic physiological processes ranging from immune modulation, control of prolifer-
ation, apoptosis to antitumor activity. However, type I IFNs were recently also shown to
apply both beneﬁcial and detrimental effects to the central nervous system (CNS) and a
tightly balanced equilibrium between cellular activation and inhibition seems to be essential
to maintain homeostasis within the CNS. In inﬂammatory pathologies affecting the CNS,
type I IFNs are in the center of attention not only because interferon beta (IFN-β) is used
as a standard therapeutic in the treatment of relapsing–remitting multiple sclerosis (MS),
but also as type I IFN expression is associated with distinct pathologies. Despite the great
efﬁciency of IFN-β in reducing MS relapses and attenuation of novel inﬂammatory lesions
is well documented, underlying molecular mechanisms and cellular target speciﬁcities are
just beginning to emerge. In contrast to the curative effects, aberrant activation of the
type I IFN response were also recently shown to be associated with detrimental effects
exempliﬁed by the Aicardi–Goutières syndrome (AGS), a severe disabling autoimmune
inﬂammatory encephalopathy. This review will highlight the dual role of type I interferons
during chronic CNS inﬂammation. Recently uncovered molecular and cellular mechanisms
in the etiology of AGS and experimental autoimmune encephalomyelitis (EAE), the murine
model of MS will be highlighted.
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TYPE I INTERFERONS AND THEIR INDUCTION
Interferons (IFNs) represent a family of cytokineswhichwere orig-
inally identiﬁed by their ability to mediate antiviral effects. Since
their discovery more than 54 years ago (Lindenmann et al., 1957),
this class of proteins now embraces around 30 members. Based
on common structural, biochemical, and signaling properties as
well as the source of cells producing these factors, IFNs can be
classed into three distinct subfamilies namely type I, type II, and
class III IFNs. While IFN-γ is the sole type II IFN and the three
different IFN-λs constitute the type III IFNs, type I IFNs are a
highly divergent group of cytokines encompassing 13 different
IFN-α subtypes, IFN-β, IFN-κ, IFN-ε, IFN-ω, IFN-τ, IFN-δ and
three different IFN-ζs (IL-28A/B and IL-29; Noppert et al., 2007).
Consistent with the functional role of type I IFNs in pathogen
defense, inductionof these cytokines is predominantly triggeredby
distinct pathogen-associated molecular patterns (PAMPs) which
are recognized by speciﬁc pathogen recognition receptors (PRRs).
As depicted in Figure 1, the surface toll-like receptor (TLR) 4
recognizing lipopolysaccharide from Gram-negative bacteria as
well as TLRs 3, 7, 8, and 9, which recognize pathogen-derived
nucleic acids, induce type I IFNs (Blasius and Beutler, 2010). TLR3
recognizes viral double-stranded RNA (dsRNA) while viral single-
stranded RNA (ssRNA) is detected by TLR7 and TLR8. Viral or
bacterial unmethylated DNA, commonly referred to as CpG DNA,
is sensed by TLR 9 (Akira et al., 2006; Barber, 2011; Kawai and
Akira, 2011).
The localization of nucleic acid sensing TLRs at the endoplas-
mic reticulum and endosomal membranes limits the detection of
viruses by TLRs to this speciﬁc compartment. In general, signal
transduction for type I IFN induction via the TLRs mentioned
above starts with the recruitment of either Toll-IL-1 receptor
(Tir) domain-containing factor (TRIF; for TLR4, TLR3) and/or
myeloid differentiation primary response gene 88 (MyD88; for
TLR7,TLR9) to the activated receptor. Subsequent signaling events
involving the molecules interleukin-1 receptor-associated kinase
(IRAK) 1, IRAK 4, tumor necrosis associated factor (TRAF) 6
and TRAF3 activate the kinases TGF-β activated kinase 1 (TAK1)
and TANK-binding kinase 1 (TBK1). While TAK1 acts as a com-
mon activator of nuclear factor of kappa light polypeptide gene
enhancer in B cells (NF-κB) signaling via the I kappa B kinase
(IKK) complex which mediates phosphorylation and degradation
of the inhibitory component IκBα, TBK1 phosphorylates inter-
feron regulatory factor (IRF) 3 leading to its dimerization (Mori
et al., 2004; Tamura et al., 2008). Finally, dimeric IRF3 and NF-
κB translocate into the nucleus to induce type I IFN expression.
In addition, engagement of distinct TLRs also causes IRF7 phos-
phorylation, which preferentially activates IFN-α but also leads to
IFN-β induction (Honda and Taniguchi, 2006).
Alternative to the TLRs, the cell employs the retinoic acid-
inducible gene-I (RIG-I) like helicases (RLHs) RIG-I and the
melanoma differentiation-associated gene 5 (MDA5) to detect
viral infection (Pichlmair and Reis e Sousa, 2007). RIG-I detects
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FIGURE 1 | Overview of typical signaling cascades inducing type I
Interferon expression. Upon ligand engagement, several toll-like
receptors (TLRs) and RIG-I like helicases (RLHs) induce transcription of
type I interferons (IFN). TLR4 located at the cell surface is typically induced
extracellular while TLR3, TLR 7/8, andTLR9 sense pathogen-derived
single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), and
unmethylated DNA (CpG DNA) within the cell sequestered from the
cytoplasmic compartment. Intracellular TLRs are localized, trafﬁc, and
initiate signaling cascades in membrane surrounded compartments like
the endoplasmic reticulum, endosomes, lysosomes, and phagocytic
vesicles. Upon ligand binding, TLR4 is endocytosed (indicated by dashed
arrows). Downstream signaling inducing type I IFN is mediated by initial
binding to either MyD88 (TLR7/8/9) or TRIF (TLR3/4), followed by
recruitment of multicomponent protein complexes. Typically a complex
with TLR3 or TLR4 together with TRIF andTRAF3 activates the kinase
TBK1 mediating phosphorylation of IRF3, which subsequently forms
homodimers, translocates to the nucleus, and initiates type I IFN gene
expression. MyD88 recruited to TLR7/8/9 complexes with IRAK1, TRAF6,
TRAF3, and the kinasesTAK1 and IKKα, which phosphorylate and thus
activate IRF7 to drive type I IFN expression. The cytoplasmic RLHs MDA5
and RIG-I recognize longer RNAs like poly I:C or 5′-3-P-RNA respectively
and engage IPS at the mitochondrial membrane. Recruitment of a complex
containingTBK1 induces phosphorylation and thus dimerization of IRF3
followed by type I IFN gene expression. Independent fromTLR and RLH
intracellular, non-CpG DNA, and cyclic-di-GMP are sensed in a STING
dependent manner. STING interacts with RIG-I and activates type I IFN
transcription via the IRF3 axis but is also capable to recruit STAT6 to the
ER followed byTBK1 mediated STAT6 phosphorylation.
5′-triphosphate-containing RNA which for example is typical for
vesicular stomatitis virus (VSV; Hornung et al., 2006; Schlee et al.,
2009). Characteristic for MDA5 is the recognition of longer RNA
molecules as exempliﬁed by the synthetic dsRNApoly I:C or picor-
navirus genomes (Kato et al., 2006). RLHs are characterized by
a helicase domain for RNA binding and a caspase recruitment
domain (CARD) mediating protein interaction for downstream
signaling. Binding to viral RNA induces homodimerization of
these sensors resulting in the engagement of MAVS (IPS-1, VISA,
CARDIF;Kawai et al., 2005;Meylan et al., 2005; Seth et al., 2005;Xu
et al., 2005) located in the mitochondrial membrane followed by
the recruitment of TRAF3, TRAF6, TBK1, and IKKα/β. As a result
of these signaling events, IRF3, IRF7, and NF-κB are activated and
together with cJUN/ATF2 and the coactivators CBP/p300 initiate
the expression of type I IFNs (Kawai and Akira, 2011).
The observation that TLR9 deﬁcient cells are still capable to
efﬁciently mount type I IFN production when transfected with
double-stranded DNA (dsDNA) led to the search of alternative
DNA sensing molecules especially in non-plasmacytoid dendritic
cells (pDCs;Kawai andAkira, 2009). These investigations led to the
identiﬁcation of theDNA sensor endoplasmic reticulum IFN stim-
ulator (ERIS) now better known as stimulator of interferon genes
(STING)which is located in theERmembrane andplays an impor-
tant role in the induction of IFN by non-CpG intracellular DNA
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species (Ishikawa and Barber, 2008; Zhong et al., 2008). Analysis of
STING−/− mice revealed that the protein, which has no homol-
ogy to otherDNA sensors, is essential for host defense againstDNA
pathogens such as herpes simplex virus 1 (HSV-1; Ishikawa et al.,
2009). Recent work also provided strong evidence that STING also
acts as a direct sensor for the bacterial second messenger cyclic-di-
GMP,whichwas shown previously to elicit a type I IFN response in
host cells (McWhirter et al., 2009;Woodward et al., 2010; Burdette
et al., 2011). It was recently shown that STING recruits STAT6
to the endoplasmatic reticulum (ER) followed by TBK-mediated
phosphorylation. Remarkably, this STAT6 activation at the ER by
STING differs from cytokine induced STAT6 phosphorylation at
the plasma membrane as Janus kinases (JAKs) are not involved
and phosphorylation is not restricted to distinct cell types. The
virus-induced STAT6 activation also occurs in IFNAR2−/− or
IRF3−/− cells as well as in cells lacking individual JAKs providing
strong evidence that STING-triggered STAT6 activation represents
a novel signaling module. While the canonical STAT6 activation is
MAVS independent this non-canonical STAT6 activation required
the presence of MAVS and STAT6 phosphorylation is mediated by
TBK1. Consistent with a fundamental role of STAT6 in antiviral
activity, STAT6 deﬁcient mice exhibited exacerbated pathologies
when challenged with either VSV, Sendai virus, or herpes simplex
virus (Chen et al., 2011).
IFN SIGNALING
As a common feature all interferons activate the JAK– signal trans-
ducers of activation and transcription (STAT) signaling pathway.
A hallmark of type I IFNs is that they all bind and signal via the
interferon alpha receptor (IFNAR), which is a heterodimer com-
posed of interferon receptor 1 (IFNAR1) and interferon receptor
2 (IFNAR2). It is a unique feature compared to other cytokine
receptors that IFNAR can bind and mediate signaling of mul-
tiple ligands. Type I IFNs bind to the IFNAR and as a conse-
quence they activate the kinases JAKs Tyk 2 and JAK 1 which
are associated with IFNAR1 and IFNAR2 respectively and phos-
phorylate receptor tyrosine residues on the receptor (de Weerd
et al., 2007). Via SH2 domains STAT bind to the phosphotyrosines
on the receptor and become themselves phosphorylated. Phos-
phorylated STAT1 forms heterodimers with STAT2 and together
with IRF9 constitutes a transcription factor (ISGF3γ) which binds
to interferon-stimulated response elements (ISREs) of interferon-
stimulated target genes (ISGs) inducing their expression. Further
complexity is added to the system by the formation of STAT1 and
STAT3homo- andheterodimerswhich activateGAS elements con-
trolling the expression of other ISGs which are also inducible by
IFN-γ. In addition, also STAT independent pathways are activated
(Boxel-Dezaire et al., 2006). Ultimately, hundreds of ISGs, which
might vary depending on the cell type, are induced and translated
into the effector proteins responsible to mediate biological effects
like antiviral activity, control of cellular proliferation, apoptosis,
and immune regulation.
INFLAMMATORY BRAIN PATHOLOGIES ASSOCIATED WITH
ABERRANT TYPE I IFN INDUCTION
Interferon beta has proinﬂammatory properties and con-
tributes to the pathology of autoimmune diseases like systemic
lupus erythematosus (SLE), rheumatoid arthritis, and psoriasis
(Preble et al., 1982; Baechler et al., 2006). Within the central
nervous system (CNS) proinﬂammatory detrimental effects of
IFN-βwere described for Aicardi–Goutières syndrome (AGS) and
neuromyelitis optica (NMO).
Aicardi–Goutières syndrome represents a fatal genetic disease
that manifests as an encephalopathy. The disease is character-
ized by increased lymphocyte numbers in the cerebrospinal ﬂuid,
demyelinationof thewhitematter and calciﬁcationof basal ganglia
thus mimicking pathological consequences of congenital infection
which often leads tomisdiagnoses (Rice et al., 2007). One hallmark
of AGS are increased levels of IFN-α in serum and cerebrospinal
ﬂuid (Dussaix et al., 1985). Increased levels of IFN-α are also a key
feature of SLE and indeed,molecularmechanisms underlyingAGS
and SLE exhibit striking parallels allocating AGS into the group of
autoimmune diseases. Furthermore, some children with AGS also
exhibit an early onset form of SLE (De Laet et al., 2005). AGS is
inherited in an autosomal recessive trait and mutations in differ-
ent genetic loci were identiﬁed. It was shown before that recessive
mutations in the genes encoding either human 3′repair exonucle-
ase 1 (TREX1),different components of the RNASEH2 complex or
the SAM-domain HD-domain-containing protein 1 (SAMHD1)
can cause this severe inﬂammatory disease (Crow et al., 2006a,b;
Rice et al., 2009). TREX1was shown to be a 3′–5′ DNAexonuclease
preferentially binding and cleaving single-stranded DNA (ssDNA;
Mazur and Perrino, 1999, 2001). Initially appearing paradox for a
DNAse, TREX1 is predominantly localized in the cytoplasm where
the protein is associated with the endoplasmic reticulum. TREX1
is part of the SET complex and in response to oxidative stress the
protein can translocate to the nucleus and is involved in Granzyme
A-mediated apoptosis (Martinvalet et al., 2005; Chowdhury et al.,
2006). In concordance with an extranuclear function, absence of
TREX inmice andhumans results in the accumulation of cytoplas-
mic ssDNA (Yang et al., 2007; Stetson et al., 2008). It was reported
that excessive and mislocalized ssDNA originates from excision
mediated DNA repair (Yang et al., 2007). Work by Medzhitov’s
group identiﬁed TREX1 as an important negative regulator of the
interferon stimulatory DNA (ISD) response. They provided com-
pelling evidence that the ssDNA accumulating in the absence of
TREX arises from endogenous retroelements which are no longer
degraded properly by the TREX nuclease. As a consequence, the
elevated levels of ssDNA which might mimic viral infection are
sensed by an unidentiﬁed DNA sensor, initiate the ISD pathway
and activate IRF3 resulting in the production of high levels of
type I IFN and lymphocyte mobilization (Stetson et al., 2008).
In line with an aberrant activation of the innate immune system
TREX1−/− mice develop an inﬂammatory myocarditis (Morita
et al., 2004). The observed cardiomyopathy in TREX1 deﬁcient
mice might be analogous to the encephalopathy in AGS patients
associated with an autoinﬂammatory response which arises in
the absence of an infection. The observation that the pheno-
type of TREX1−/− mice can be rescued in the absence of either
IRF3, IFNAR, or the recombination activating gene (RAG) further
underlines that the autoimmune mechanism is triggered by acti-
vation of IRF3 mediated type I IFN induction (Stetson et al., 2008)
but also shows that secondary mechanisms like leukocyte recruit-
ment are essential for diseasemanifestation. In linewith the central
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role of TREX in the maintenance of immune homeostasis is the
observation that mutations in this gene are also associated with
SLE (Lee-Kirsch et al., 2007).
The central role of TREX1 as a negative regulator of type I
IFN induction is exploited by the human immunodeﬁciency virus
(HIV) type 1. Recent work showed that TREX1 not only degrades
DNA from endogenous retroelements to prevent autoimmune
activation. The nuclease is also active against HIV DNA which
arises during HIV infection after reverse transcription (RT; Gei-
jtenbeek, 2010; Yan et al., 2010). Apparently, the virus hijacks
TREX1’s speciﬁcity for retrovirus-derived DNA to avoid activa-
tion of cytoplasmic nucleic acid sensors, which usually trigger the
antiviral effector system. TREX1-mediated degradation of HIV
DNA thus represents one mechanism how HIV escapes immune
recognition and helps to explain why infection of T cells and
macrophages do not elicit an effective antiviral interferon response
(Geijtenbeek, 2010).
Interestingly, also another AGS susceptibility gene, SAMHD1,
which is highly expressed in macrophages and dendritic cells and
upregulated upon viral infection was proposed to act as a nega-
tive regulator of the innate immune response (Lafuse et al., 1995;
Li et al., 2000; Rice et al., 2009). However, the molecular func-
tion until recently remained elusive. SAMHD1 function was now
shown to be tightly linked to the control of retroviral infection
(Hrecka et al., 2011; Laguette et al., 2011). HIV is incapable to
transduce dendritic cells and impaired in the transduction of
macrophages because efﬁcient viral cDNA synthesis is inhibited
in these cells. In contrast, other retroviruses encoding Vpx acces-
sory proteins circumvent this inhibition (Ayinde et al., 2010). Two
recent publications identiﬁed SAMHD1 as the factor restricting
HIV infection in myeloid and dendritic cells and showed that
Vpx proteins counteract this restriction by mediating proteaso-
mal degradation of SAMHD1 (Hrecka et al., 2011; Laguette et al.,
2011).
Recently, also the molecular function of SAMHD1 was identi-
ﬁed. It was shown that the protein is an effective dGTP-stimulated
deoxyguanosine triphosphate triphosphohydrolase, which cat-
alyzes the conversion of dGTP to guanosine and inorganic triphos-
phate (Goldstone et al., 2011). SAMHD1 rapidly hydrolyzes dGTP
but not dATP, dCTP, and dTTP. However, SAMHD1 is alloster-
ically activated by dGTP which binds to SAMHD1 leading to a
more promiscuous substrate speciﬁcity which is extended to dATP,
dCTP, and dTTP. dGTP is thus both a substrate and an activator of
the enzyme against the other dNTPs. The catalytic activity should
strongly limit the dNTP pool within the cytoplasm and thus exert
a role in nucleic acid metabolism. It is reasonable to hypothe-
size that SAMHD1 limits the dNTP pool and thus interferes with
HIV replication by inhibiting endogenous RT. With respect to the
etiology of AGS, loss of SAMHD1 activity would no longer coun-
teract RT of endogenous retroviral elements as the dNTP pool is
no longer restricted. As a consequence, the loss of RT restriction
might promote the accumulation of cytoplasmic DNA similar to
what is observed in TREX1 mutants. Although further experimen-
tal evidence needs to be added, this model would be a straight
forward explanation for the similar phenotypic manifestations
arising from human mutations in SAMHD1 and TREX genes.
In summary, TREX1 and SAMHD1 provide excellent examples
for the intricate relationship between the control of retroviral
infection and the control of cell intrinsic nucleic acids harbor-
ing the risk to trigger autoimmune inﬂammation induced by
type I IFNs.
In addition, also mutations in subunits of the RNase H2 com-
plex were shown to cause AGS (Crow et al., 2006b). The RNase H2
is the dominant cytoplasmic RNase in human cells and composed
of a heterotrimeric complex in which all three components are
needed to constitute the active enzyme. RNase H2 enzymes rec-
ognize RNA:DNA hybrids, degrade the polyribonucleotide strand
and thus also play a central role in nucleic acid metabolism (Eder
and Walder, 1991; Rydberg and Game, 2002). Although direct
experimental evidence is still missing, it is likely that RNase H2
mutations which impair degradation of RNA:DNA hybrids alter
cytoplasmic nucleic acid homeostasis resulting in the activation of
the ISD response.
As depicted in Figure 2, analysis of the molecular mecha-
nisms underlyingAGS revealed a role of all the susceptibility genes
mentioned above in the control of cytoplasmic nucleic acid home-
ostasis which needs to be tightly controlled in order to prevent
autoimmunity induced by type I IFNs.
NEUROMYELITIS OPTICA (DEVIC’S DISEASE) AND TYPE I
IFNs
Neuromyelitis optica represents a neuroinﬂammatory disease pre-
viously considered to be a variant of relapsing–remitting multiple
sclerosis (RRMS). However, in contrast to RRMS, NMO is char-
acterized by demyelination in the spinal cord and optic nerve
(Lucchinetti et al., 2002). Autoantibodies directed against the
aquaporin 4 water channel are found in these patients and occur-
rence of anti-aquaporin antibodies also is the major parameter
in the diagnosis of NMO (Paul et al., 2007). Driven by the sup-
posed analogy to RRMS, IFN-β was tried as a therapeutic but it
was quickly clear that IFN-β treatment even worsens the disease
and induces severe relapses (Warabi et al., 2007; Palace et al., 2010;
Shimizu et al., 2010; Uzawa et al., 2010). Notably, the dominant
inﬁltrating cells are granulocytes which is in sharp contrast to
classical multiple sclerosis (MS). This clearly different inﬁltratory
make up might explain the different response upon IFN-β treat-
ment. Interestingly, levels of IL-17 were found to be elevated in
the cerebrospinal ﬂuid of people suffering from NMO and it has
been proposed that IL-17 mediated induction of IL-8, granulo-
cyte stimulating factor (G-CSF) and Gro-alpha causes granulocyte
recruitment (Axtell et al., 2011).
ANTI-INFLAMMATORY EFFECTS OF TYPE I IFNs IN
RELAPSING–REMITTING MULTIPLE SCLEROSIS AND
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
As exempliﬁed for SLE and AGS, type I IFNs were frequently
causally associatedwith the development of autoimmune patholo-
gies. In contrast, type I IFNs were also shown to exert anti-
inﬂammatory effects and IFN-β is used as a routine therapeutic
for the treatment of RRMS in patients (Jacobs et al., 2000; Filippi
et al., 2004). MS is an autoimmune inﬂammatory disease of the
CNS of unclear etiology characterized by demyelination of axons
in brain and spinal cord. Characteristic for the disease is the inﬁl-
tration of the CNS with inﬂammatory cells like monocytes, TH1
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FIGURE 2 | Model for the role of cytoplasmic nucleic acid homeostasis
in the etiology of Aicardi–Goutieres syndrome (AGS).TREX1 is an 5′–3′
Exonuclease which degrades cytoplasmic single-stranded DNA (ssDNA)
originating from reverse transcription of endogenous retrotransposons.
Lack of TREX1 activity results in the congestion of ssDNA thereby
augmenting the pool of nucleic acids in the cytoplasm. SAMHD1 cleaves
inorganic triphosphate from deoxynucleotides and thus restricts the
cytoplasmic dNTP concentrations hence constraining reverse transcription
by limiting the amount of “building blocks” for DNA synthesis. SAMHD1
mutations would eliminate this dNTP control mechanism, enhance the
dNTP pool, and could thus fuel reverse transcription from endogenous
retroelements resulting in increased levels of cytoplasmic ssDNA.
RNASEH2 is an endonuclease composed of three subunits and required to
cleave ribonucleotides from RNA:DNA duplexes which arise from
intracellular processes. Lack of function mutations in RNASeH2 would
thus also impair the control of nucleic acid homeostasis. Thus mutations in
any kind of the genes mentioned above which were found in AGS patients
would lead to the accumulation of nucleic acids in the cytoplasm. These
aberrant levels are sensed by cytoplasmic DNA sensors originally
designated to detect viral infections. Consequently the initiated signaling
cascade activates interferon regulatory transcription factors (IRFs) for type
I IFN induction and drive autoimmune disease onset.
and TH17 cells. In RRMS, phases with no or only minor disease
progression are followed by unpredictable acute relapses causing
deﬁcits which might at least partially resolve in times of remission.
According to results from clinical trials, IFN-β treatment
reduces relapse rates by about 30%, decreases the formation of
inﬂammatory lesions in the CNS and extends remission periods
(Schwid and Panitch, 2007). However, a major problem is that
a high proportion of about 20% of the patients do not or only
poorly respond to IFN-β treatment. Despite excessive attempts to
deﬁne biomarkers for responders and non-responders it is still
impossible to predict whether an individual patient will respond
to IFN-β therapy. Mechanism underlying this variety include
development of antibodies against IFN-β, polymorphisms in com-
ponents of the IFN signaling pathway and IFN effector genes as
well as variable MS pathomechanisms (Killestein and Polman,
2011). By further dissecting type I IFN signatures in MS patients,
IFN-β non-responders were found to exhibit increased monocyte-
speciﬁc type I IFN secretion upon innate immune stimuli via TLR
4, by increased endogenous production of type I interferon, and
by an elevated activation status of myeloid dendritic cells (Coma-
bella et al., 2009). These ﬁndings indicate that perturbations of the
type I IFN signaling pathway in monocytes are related to a lack of
response to IFN-β and type I IFN-regulated genes may be used as
response markers in IFN-β treatment in MS. Consistent with the
concept that genetic variants deﬁne the individual response is that
induction of interferon response genes among different patients
varies signiﬁcantly but is remarkably stable within a long time
period.
A frequently used system to gain insight into the molecular
and cellular events underlying MS is the model of experimen-
tal autoimmune encephalomyelitis (EAE). In this well-established
mouse model active immunization with myelin components
together with a strong adjuvant induces T-cell mediated neuroin-
ﬂammation and demyelination resembling multiple aspects of MS
(Owens et al., 2001; Gold et al., 2006).
Consistent with the beneﬁcial effect of IFN-β in human MS,
EAE in rodents can be suppressed by injection of recombinant
IFN-β. In addition, mice lacking IFN-β exhibit strongly exacer-
bated disease parameters in the EAE model (Teige et al., 2003).
Furthermore, IFNβ is stronger induced in the CNS than in the
periphery. To trace down the cell type mediating the “protec-
tive” immune regulation of type I IFNs via the type I receptor
(IFNAR), mice lacking this receptor only on distinct cell types
were used for EAE experiments and IFN-β treatment (Prinz et al.,
2008). It could be shown that negative regulation of autoimmu-
nity in the EAE model relies on the presence of IFNAR on cells of
the myeloid lineage while absence of IFNAR on T cells, B cells,
and cells of neuroectodermal origin does not enhance disease
severity. These experiments suggest a scenario where locally pro-
duced IFN-β within the CNS acts on invading myeloid cells to
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attenuate autoimmune damage especially in the effector phase of
EAE. Another study which also employed EAE in IFNAR deﬁcient
mice provided evidence for a functional role of type I interferon
in negatively regulating the development of TH17 cells. Num-
bers of encephalitogenic TH17 cells were found by this group
to be elevated after EAE induction in IFNAR1 and TRIF deﬁ-
cient mice (Guo et al., 2008). TH17 cells develop from naive
T cells which induced by TGFβ and IL-6 secrete IL-21. This
cytokine subsequently induces the transcription factor RORγt
in an autocrine manner which triggers the TH17 differentiation
program (Veldhoen et al., 2006; Stockinger and Veldhoen, 2007).
IFN-β induces expression of IL-27 which acts on naive CD4+
T cells as a negative regulator of TH17 development (Prinz and
Kalinke, 2010). IL-27 also promotes IL-10 secretion by T cells
which was shown to suppress autoimmune inﬂammation of the
CNS (Fitzgerald et al., 2007). IFN-β was furthermore shown to
inhibit IL-23 induced proliferation of TH17 cells (Harrington
et al., 2005). Increased levels of TH17 cells in IFNAR−/− mice
would thus be explained by the lack of these inhibitory effects of
type I IFNs.
Disease symptoms and generation of antigen speciﬁc TH17
cells were also enhanced in TRIF deﬁcient mice suggesting that
type I IFN production counteracting autoimmunity in EAE is
triggered by a TRIF dependent mechanism (Guo et al., 2008).
Interestingly, type I IFN-related genes were found to be strongly
induced in toxicmousemodels of demyelinationwhereas the pres-
ence of IFNAR could neither modulate demyelination or myelin
repair (Schmidt et al., 2009).
Just recently, also cytosolic RLHs were shown to act as neg-
ative regulators of sterile inﬂammation within the CNS (Dann
et al., 2012). Mice lacking the RIG-I like helicase adaptor IPS-1
developed exacerbated disease symptoms. In a reciprocal exper-
iment the same study showed that on the other hand activation
of RLHs via IFN-inducing 5′-triphosphate RNA oligonucleotides
ameliorated disease outcome providing compelling evidence that
RLHs mediate signals counteracting encephalitogenic immune
responses. While RLH stimulation did not affect T-cell differenti-
ation, the maintenance and expansion of TH1 and TH17 cells was
strongly suppresseduponRLHengagement (Figure 3). Repression
of proinﬂammatory TH1 and TH17 cells could only be observed
FIGURE 3 | Model for negative regulation of sterile CNS
inflammation by RIG-I like helicases (RLHs). In dendritic cells
activation of RLHs RIG-I or MDA5 by 5′triphosphate RNA or polyI:C
complexed to liposomes (cPolyI:C) respectively, recruits IPS-1 to the
RLH. This initiates a signaling cascade which involvesTBK1 mediated
phosphorylation of IRF3 and/or IRF7 which upon dimerization enter the
nucleus and lead to the expression of type I IFN. Secreted type IFNs
(IFN) can either bind to type I interferon receptor (IFNAR) in an autocrine
or paracrine manner and stimulate the expression of
interferon-stimulated target genes (ISGs). While lack of IPS-1 leads to
exacerbated disease pathology in the EAE model of sterile inﬂammation,
RLH stimulation improved clinical signs of disease and inhibits TH1 and
TH17 expansion and survival. This regulation is type I IFN mediated as the
“therapeutic effect” of RLH stimulation is abrogated in IFNAR deﬁcient
mice. However, mice speciﬁcally lacking IFNAR on monocytes,
macrophages, microglia, or granulocytes like wildtype mice showed
reduced symptoms upon RLH induction. IFNAR signaling on these cells
is thus dispensable for the suppressive effect of RLH engagement. In
contrast, when mice speciﬁcally lacking IFNAR on dendritic cells were
used, RLH treatment did not ameliorate autoimmunity clearly showing
that interferon stimulation in this particular celltype is essential for IFN
mediatedTH1 andTH17 inhibition and disease improvement.
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when the type I interferon receptor was present on dendritic cells
by usingCD11cCremice crossedwith conditional IFNAR animals.
Remarkably, absence of IFNAR1 on macrophages or microglia did
not interfere with RLH mediated TH1 or TH17 repression (Dann
et al.,2012). These results imply that engagementof RLHsmight be
a passable way to stimulate endogenous type I IFNs for therapeutic
intervention. Replacing systemic administration with the endoge-
nous induction of type I IFNs should prevent the development
of neutralizing antibodies. It might also be more effective than
systemic administration as type I IFNs are biologically designed
to exert their effects in a spatially restricted area affecting cells in
their direct neighborhood.
Recognition of triphosphate RNA by RIG-I like helicases fol-
lowed by IFN induction is largely independent from the sequence
used for the dsRNA (Hornung et al., 2006). Thus, a speciﬁc short
interfering RNA (RNAi) suitable to suppress expression of a spe-
ciﬁc target protein can be used. This, at least in principle, offers
therapeutic strategies where activation of the type I IFN response
can be combined with the suppression of harmful gene products.
As a proof of principle for the feasibility of such an approach it was
shown in a melanoma model that BCL2 speciﬁc siRNA carrying 5′
triphosphate ends efﬁciently activated type I IFN via RIG-I and in
parallel silenced Bcl2 expression (Poeck et al., 2008). As a conse-
quence, the synergistic activation of the innate immune response
combined with suppression of a pro survival signal caused massive
apoptosis of tumor cells, prolonged survival of the animals, and
reduced tumor size.
It might thus also be suitable to combine type I IFN induc-
tion with RNAi mediated inhibition of proinﬂammatory factors
or proteins triggering the differentiation of deleterious cells. Such
a strategy where for example type I IFN induction could be com-
bined with RNAi mediated inhibition of RORγt or T-bet to simul-
taneously repress TH17 and TH1 differentiation might potentially
open new ways to modulate the immune response and counteract
autoimmunity within the CNS.
CONCLUSION AND FUTURE PERSPECTIVES
Despite extensively analyzed, the functions of type I IFNs within
the CNS are still far from being well understood. One principal
problem to generalize type I IFN effects is surely based on the fact
that hundreds of genes,which even vary among different cell types,
are controlled by this particular group of cytokines. In addition,
the levels and kind of IFN target genes induced are differentially
regulated depending on the situation, interaction and environ-
ment of the cell. Further complexity is added to the system as
multiple negative regulators of the IFN signaling system modulate
the outcome and refractory mechanisms blunt restimulation. A
major task for the futurewill be to identify the particular interferon
effector genes responsible for the anti-inﬂammatory and thera-
peutic properties which even might considerably differ between
various cell types. With respect to the etiology of type I IFN asso-
ciated autoimmune disease like AGS it will be interesting to see
which particular molecules are involved in the pathways sensing
enhanced levels of endogenous nucleic acids in the cytoplasm.
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